Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis

Cell Death and Disease

Volumn 2, Issue 3, 2011, Pages

  Ahmad, I ^a   Patel, R ^a   Liu, Y ^b   Singh, L B ^a   Taketo, M M ^c   Wu, X R ^b   Leung, H Y ^a   Sansom, O J ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

catenin; Bladder cancer; H Ras; Urothelial cell carcinoma; Wnt

Indexed keywords

BETA CATENIN; P21 ACTIVATED KINASE 1; RAS PROTEIN; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER TUMOR; CANCER GROWTH; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; UPREGULATION; UROTHELIUM; ANIMAL; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MUTATION; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

MUS;

ANIMALS; BETA CATENIN; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC; MUTATION; NEOPLASTIC PROCESSES; RAS PROTEINS; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS; WNT PROTEINS;

EID: 79959645720     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2011.7     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
2. Cordon-Cardo C. Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol Suppl 2008; 218: 154-165.
3. Diaz DS, Segersten U, Malmstrom PU. Molecular genetics of bladder cancer: an update. Minerva Urol Nefrol 2008; 60: 205-216.
4. Luis NM, Lopez-Knowles E, Real FX. Molecular biology of bladder cancer. Clin Transl Oncol 2007; 9: 5-12.
5. Schulz WA. Understanding urothelial carcinoma through cancer pathways. Int J Cancer 2006; 119: 1513-1518. (Pubitemid 44258755)
6. Reddy EP, Reynolds RK, Santos E, Barbacid M. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 1982; 300: 149-152. (Pubitemid 12006347)
7. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 2010; 5: e13821.
8. Czerniak B, Cohen GL, Etkind P, Deitch D, Simmons H, Herz F et al. Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Hum Pathol 1992; 23: 1199-1204.
9. Zhang ZT, Pak J, Huang HY, Shapiro E, Sun TT, Pellicer A et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 2001; 20: 1973-1980. (Pubitemid 32458029)
10. Vageli D, Kiaris H, Delakas D, Anezinis P, Cranidis A, Spandidos DA. Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors. Cancer Lett 1996; 107: 241-247. (Pubitemid 26381996)
11. Ayan S, Gokce G, Kilicarslan H, Ozdemir O, Yildiz E, Gultekin EY. K-RAS mutation in transitional cell carcinoma of urinary bladder. Int Urol Nephrol 2001; 33: 363-367. (Pubitemid 34575390)
12. Uchida T, Wada C, Ishida H, Egawa S, Ao T, Yokoyama E et al. Infrequent involvement of mutations on neurofibromatosis type 1, H-ras, K-ras and N-ras in urothelial tumors. Urol Int 1995; 55: 63-67.
13. Olderoy G, Daehlin L, Ogreid D. Low-frequency mutation of Ha-ras and Ki-ras oncogenes in transitional cell carcinoma of the bladder. Anticancer Res 1998; 18: 2675-2678. (Pubitemid 28390393)
14. Ahmad I, Morton JP, Singh LB, Radulescu SM, Ridgway RA, Patel S et al. β-catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene 2011; 30: 178-189.
15. Lu ML, Wikman F, Orntoft TF, Charytonowicz E, Rabbani F, Zhang Z et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res 2002; 8: 171-179. (Pubitemid 34101474)
16. Stein JP, Ginsberg DA, Grossfeld GD, Chatterjee SJ, Esrig D, Dickinson MG et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998; 90: 1072-1079. (Pubitemid 28350272)
17. Shariat SF, Kim J, Raptidis G, Ayala GE, Lerner SP. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 2003; 61: 1140-1145. (Pubitemid 36693989)
18. Marsit CJ, Karagas MR, Andrew A, Liu M, Danaee H, Schned AR et al. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res 2005; 65: 7081-7085. (Pubitemid 41161235)
19. Urakami S, Shiina H, Enokida H, Kawakami T, Kawamoto K, Hirata H et al. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res 2006; 12(7 Part 1): 2109-2116.
20. Urakami S, Shiina H, Enokida H, Kawakami T, Tokizane T, Ogishima T et al. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/β-catenin signaling pathway. Clin Cancer Res 2006; 12: 383-391. (Pubitemid 43166125)
21. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243-3248. (Pubitemid 34008190)
22. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW,Wang X, Shen TH, Matos T et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009; 23: 675-680.
23. Park KS, Jeon SH, Kim SE, Bahk YY, Holmen SL, Williams BO et al. APC inhibits ERK pathway activation and cellular proliferation induced by RAS. J Cell Sci 2006; 119(Part 5): 819-827.
24. Yun MS, Kim SE, Jeon SH, Lee JS, Choi KY. Both ERK and Wnt/β-catenin pathways are involved in Wnt3a-induced proliferation. J Cell Sci 2005; 118(Part 2): 313-322. (Pubitemid 40277344)
25. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139: 1327-1341.
26. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA 2010; 107: 246-251.
27. Morton JP, Jamieson NB, Karim SA, Athineos D, Ridgway RA, Nixon C et al. LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology 139: 586 597.e1-6.
28. Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res 1999; 59: 3512-3517. (Pubitemid 29334516)
29. Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M et al. Intestinal polyposis in mice with a dominant stable mutation of the β-catenin gene. EMBO J 1999; 18: 5931-5942. (Pubitemid 29515670)
30. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675-684.
31. Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R et al. Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 2006; 48: 787-794. (Pubitemid 43800937)